Clinical trial • Phase III • Oncology
RMC-6291 for Non-small cell lung cancer | Pancreatic adenocarcinoma | Colorectal cancer
Phase III trial of RMC-6291 for Non-small cell lung cancer | Pancreatic adenocarcinoma | Colorectal cancer. 100 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Non-small cell lung cancer | Pancreatic adenocarcinoma | Colorectal cancer
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 19-02-2024
- First CTIS Authorization Date
- 10-06-2024
Trial design
Phase III trial across 32 sites in Italy, Germany, Netherlands and others.
- Biomarker Stratified
- True - KRASG12C mutation (enrolment biomarker)
- Single Multiple Or Escalation Dose Combined
- Yes
- Target Sample Size
- 100
Eligibility
Recruits 100 Vulnerable population selected; no details provided on consent or assent handling..
- Vulnerable Population
- Vulnerable population selected; no details provided on consent or assent handling.
Recruitment
- Planned Sample Size
- 100
- Recruitment Window Months
- 31
Geography
- Total Number Of Sites
- 32
- Total Number Of Participants
- 110
Italy
- Earliest CTIS Part Ii Submission Date
- 27-05-2024
- Latest Decision Or Authorization Date
- 23-12-2025
- Processing Time Days
- 575
- Number Of Sites
- 8
- Number Of Participants
- 30
Sites
- Site Name
- IRCCS Istituto Nazionale Tumori Fondazione Pascale
- Department Name
- Melanoma, Cancer Immunotherapy and Development Therapeutics
- Contact Person Name
- Paolo Antonio Ascierto
- Contact Person Email
- p.ascierto@istitutotumori.na.it
- Site Name
- Azienda Ospedaliero-Universitaria San Luigi Gonzaga
- Department Name
- Oncology
- Contact Person Name
- Silvia Novello
- Contact Person Email
- silvia.novello@unito.it
- Site Name
- Azienda Ospedaliero Universitaria Delle Marche
- Department Name
- Medical Oncology
- Contact Person Name
- Rossana Berardi
- Contact Person Email
- rossana.beradi@ospedaliriuniti.marche.it
- Site Name
- Centro Di Riferimento Oncologico Di Aviano
- Department Name
- Medical Oncology
- Contact Person Name
- Alessandra Bearz
- Contact Person Email
- a.bearz@cro.it
- Site Name
- Azienda Ospedaliero Universitaria Parma
- Department Name
- Medical Oncology
- Contact Person Name
- Marcello Tiseo
- Contact Person Email
- mtiseo@ao.pr.it
- Site Name
- ASST Grande Ospedale Metropolitano Niguarda
- Department Name
- Medical Oncology
- Contact Person Name
- Alessio Amatu
- Contact Person Email
- alessio.amatu@ospedaleniguarda.it
- Site Name
- Azienda Unita Sanitaria Locale Della Romagna
- Department Name
- Oncohematological
- Contact Person Name
- Manolo D'Arcangelo
- Contact Person Email
- manolo.darcangelo@auslromagna.it
- Site Name
- Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
- Department Name
- Simple Departmental Structure of Thoracic Oncology
- Contact Person Name
- Angelo Delmonte
- Contact Person Email
- angelo.delmonte@irst.emr.it
Germany
- Earliest CTIS Part Ii Submission Date
- 27-05-2024
- Latest Decision Or Authorization Date
- 05-01-2026
- Processing Time Days
- 588
- Number Of Sites
- 4
- Number Of Participants
- 20
Sites
- Site Name
- Stiftung Krankenhaus Bethanien Fuer Die Grafschaft Moers
- Department Name
- Klinik für Lungen- & Bronchialheilkunde
- Contact Person Name
- Karl-Otto Kambartel
- Contact Person Email
- Kambartel@bethanienmoers.de
- Site Name
- Klinikum Esslingen GmbH
- Department Name
- Klinik für Kardiologie, Angiologie und Pneumologie
- Contact Person Name
- Martin Faehling
- Contact Person Email
- M.Faehling@klinikum-esslingen.de
- Site Name
- Klinikum Nuernberg
- Department Name
- Hematology and Medical Oncology
- Contact Person Name
- Stefan Knop
- Contact Person Email
- Stefan.knop@klinikum-nuerrnberg.de
- Site Name
- University Hospital Cologne AöR
- Department Name
- Internal Medicine/ Center for Integrated Oncology
- Contact Person Name
- Jürgen Wolf
- Contact Person Email
- juergen.wolf@uk-koeln.de
Netherlands
- Earliest CTIS Part Ii Submission Date
- 27-05-2024
- Latest Decision Or Authorization Date
- 22-12-2025
- Processing Time Days
- 574
- Number Of Sites
- 1
- Number Of Participants
- 10
Sites
- Site Name
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Department Name
- Medical Oncology
- Contact Person Name
- Frans Opdam
- Contact Person Email
- f.opdam@nki.nl
Spain
- Earliest CTIS Part Ii Submission Date
- 16-05-2024
- Latest Decision Or Authorization Date
- 23-12-2025
- Processing Time Days
- 586
- Number Of Sites
- 11
- Number Of Participants
- 20
Sites
- Site Name
- MD Anderson Cancer Center
- Department Name
- Oncology
- Contact Person Name
- Fernando Fabio Franco
- Contact Person Email
- ffranco@fundacionmdanderson.es
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Medical Oncology
- Contact Person Name
- Mariano Ponz-Sarvise
- Contact Person Email
- mponz@unav.es
- Site Name
- Hospital Universitario Quironsalud Madrid
- Department Name
- Medical Oncology
- Contact Person Name
- Valentina Boni
- Contact Person Email
- vboni@nextoncology.eu
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Oncology
- Contact Person Name
- Luis Paz-Ares
- Contact Person Email
- lpazares@hotmail.com
- Site Name
- Hospital Unviersitario Miguel Servet
- Department Name
- Medical Oncology
- Contact Person Name
- Angel Artal
- Contact Person Email
- aartalc@salud.aragon.es
- Site Name
- Hospital Universitario Y Politecnico La Fe
- Department Name
- Oncology
- Contact Person Name
- Francisco de Asis Aparisi Aparisi
- Contact Person Email
- francisco_aparisi@iislafe.es
- Site Name
- Hospital Hm Nou Delfos
- Department Name
- Oncology
- Contact Person Name
- Tatiana Hernandez Guerrero
- Contact Person Email
- Tatiana.hernandez@start-barcelona.com
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Oncology
- Contact Person Name
- Bernard Doger
- Contact Person Email
- Bernard.doger@startmadrid.com
- Site Name
- Institut Catala D'oncologia
- Department Name
- Oncology
- Contact Person Name
- Jose Carlos Ruffinelli Rodriguez
- Contact Person Email
- jruffinelli@iconcologia.net
- Site Name
- Clinica Universidad De Navarra (Madrid site)
- Department Name
- Medical Oncology
- Contact Person Name
- Mariano Ponz-Sarvise
- Contact Person Email
- mponz@unav.es
- Site Name
- Hospital Universitario Virgen De La Macarena
- Department Name
- Medical Oncology
- Contact Person Name
- David Vincente Baz
- Contact Person Email
- dvicentebaz@yahoo.es
France
- Earliest CTIS Part Ii Submission Date
- 14-03-2024
- Latest Decision Or Authorization Date
- 23-12-2025
- Processing Time Days
- 649
- Number Of Sites
- 8
- Number Of Participants
- 30
Sites
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- Oncology Medical Department
- Contact Person Name
- Elvire Pons-Tostivint
- Contact Person Email
- elvire.pons@chu-nantes.fr
- Site Name
- Institut De Cancerologie De L Ouest
- Department Name
- Oncology Department
- Contact Person Name
- Frederic Bigot
- Contact Person Email
- Frederic.bigot@ico.unicancer.fr
- Site Name
- Centre Leon Berard
- Department Name
- Medical Oncology
- Contact Person Name
- Loic Verlingue
- Contact Person Email
- loic.verlingue@lyon.unicancer.fr
- Site Name
- Institut Bergonie
- Department Name
- Medical Oncology
- Contact Person Name
- Sophie Cousin
- Contact Person Email
- s.cousin@bordeaux.unicancer.fr
- Site Name
- Centre Oscar Lambret
- Department Name
- Medical Oncology
- Contact Person Name
- Loïc Lebellec
- Contact Person Email
- l-lebellec@o-lambret.fr
- Site Name
- Institut De Cancerologie Strasbourg Europe
- Department Name
- Medical Oncology
- Contact Person Name
- Lauriane Eberst
- Contact Person Email
- l.eberst@icans.eu
- Site Name
- Institut Regional Du Cancer De Montpellier
- Department Name
- Medical Oncology
- Contact Person Name
- Diego Tosi
- Contact Person Email
- Diego.Tosi@icm.unicancer.fr
- Site Name
- Hospices Civils De Lyon
- Department Name
- Pulmonology
- Contact Person Name
- Michael Duruisseaux
- Contact Person Email
- michael.duruisseaux@chu-lyon.fr
Sponsor
Primary sponsor
- Full Name
- Revolution Medicines Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- RMC-6291
- Investigational Product Name
- RMC-6236
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)